Objectives of this Study:
# To define, measure, and describe the global human liver model market by type and region.
# To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities).
# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.
# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
# To forecast the size of market segments in North America, Europe, Asia Pacific, and RoW
The global human liver models market is expected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6% during the forecast period (2017-2022).
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468
The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure.
Target Audience:
# Pharmaceutical and biotechnology companies
# Chemical companies
# Cosmetic product manufacturers, suppliers, and distributors
# Healthcare providers and diagnostic laboratories
# Manufacturers of 3D Cell Culture products
# Food & beverage manufacturers
# Contract research organizations (CROs)
# Research institutes/universities
# Research and consulting firms
# Venture capitalists
North America held the largest share of the market in 2017
In 2017, North America accounted for the largest share of the human liver models market, followed by Europe.
The market for human liver models in this region is driven by the presence of a well-established life sciences industry, growing awareness about the organoids technology, favorable government initiatives, growing incidence of NAFLD, and unavailability of livers for transplantation, increased research spending, rising focus on tissue culture-based clinical diagnostics, and the availability of skilled professionals.
The human liver models market is emerging and fragmented in nature with various regional and international players. In 2016, the liver-on-a-chip and liver 3D bioprinting market was dominated by CN Bio (UK) and Organovo Holdings, Inc. (US), respectively.
The key players in the global human liver models market are Emulate (US), Ascendance Bio (US), HìREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan).
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468
